Conversely, GOT2 had markedly lower expression in CHOL (Cholangiocarcinoma), GBM (Glioblastoma), KIRC (Kidney renal clear cell carcinoma), LIHC (Liver hepatocellular carcinoma), PRAD (Prostate adenocarcinoma) and THCA (Thyroid carcinoma). Here, GOT2 is linked to glioblastoma.